Aclaris Therapeutics, Inc. (ACRS)

↓ Download CSV

CIK 0001557746 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Aclaris Therapeutics, Inc. reported revenue of $7.83M, down 58.2% from the prior year. The company ran a net loss, with a net margin of -829.6%. It held $160.46M in total assets against $57.38M in total liabilities.

Key ratios (FY2025)

-975.9%
Operating margin
-829.6%
Net margin
-63.0%
Return on equity
-58.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$7.83M$18.72M$31.25M$29.75M$6.76M$6.48M$4.23M$6.15M$1.68M
Cost of Revenue$2.09M$2.79M$3.42M$4.02M$4.71M$5.13M$4.05M$4.33M$1.21M
Gross Profit$3.24M$476.0K
Operating Income-$76.38M-$141.93M-$97.36M-$89.85M-$89.72M-$50.91M-$111.06M-$84.78M-$54.36M-$48.57M
Net Income-$64.92M-$132.06M-$88.48M-$86.91M-$90.86M-$51.02M-$161.35M-$132.74M-$68.52M-$48.08M
EPS (Diluted)$-0.53$-1.71$-1.27$-1.33$-1.60$-1.20$-3.90
Total Assets$160.46M$220.33M$197.41M$254.60M$251.21M$70.78M$98.30M$275.57M$243.51M$176.09M
Total Liabilities$57.38M$64.77M$40.23M$56.98M$53.87M$33.13M$28.39M$60.44M$18.25M$6.59M
Shareholders' Equity$103.08M$155.55M$157.18M$197.62M$197.34M$37.65M$69.91M$215.12M$225.26M$169.49M
Cash & Equivalents$19.96M$24.57M$39.88M$45.28M$27.35M$22.06M$34.19M$20.20M$30.17M
Operating Cash Flow-$47.11M-$20.07M-$78.33M-$67.57M-$52.13M-$38.63M-$96.44M-$100.81M-$54.66M-$34.60M
Capital Expenditures$111.0K$121.0K$1.31M$605.0K$308.0K$453.0K$1.61M$1.36M$1.24M$232.0K
Shares Outstanding120.50M107.85M70.89M66.69M61.23M45.11M41.49M41.21M30.86M26.06M